ClinicalTrials.gg
CompletedNCT07198087Updated Jun 26, 2026

A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

A Phase 1 interventional study of Tirabrutinib in Primary Central Nervous System Lymphoma (PCNSL), sponsored by Ono Pharmaceutical Co., Ltd.. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

A study to investigate the pharmacokinetics of tirabrutinib in participants with mild, moderate, and severe hepatic impairment compared to healthy participants

02

Conditions studied

  • Primary Central Nervous System Lymphoma (PCNSL)

Keywords

  • 4059
  • 4059-16
  • Tirabrutinib
03

In context

Lead sponsor

Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants, age 18 to 75, inclusive, at the time of .
  • between 18 and 40 kg/m2, inclusive, at Screening.
  • Continuous non-smokers or smokers who smoke 20 cigarettes or fewer per day.
  • Willingness and ability to swallow study intervention tablets.
  • Estimated (eGFR) of 45 mL/minute or higher calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 creatinine equation at Screening.
  • Chronic and stable hepatic impairment conforming to classification A, B, or C, and documented by medical history and a physical examination.
  • Adequate bone marrow, renal, and hepatic function at Screening.
  • Healthy participants matched to participants with hepatic impairment with regard to sex, BMI (±20%) and age (±10 years), and determined to have no deviations from normal in their medical history, physical examination, , and clinical laboratory determinations.

Exclusion criteria

Exclusion Criteria:

  • Participant is mentally or legally incapacitated or has significant emotional problems at the time of the Screening visit or such issues can be expected during the conduct of the study.
  • History of liver transplant.
  • History of any major invasive surgery within 28 days before dosing, or minor invasive surgery within 7 days before dosing.
  • Presence of any , ongoing systemic bacterial, fungal, or viral infections (including upper respiratory tract infections, but excluding localized cutaneous fungal infections), based on the judgement of the investigator or history of an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic within 28 days before dosing.
  • History or suspicion of interstitial lung disease.
  • History of stroke or intracranial hemorrhage within 6 months before dosing.
  • History of bleeding diathesis (eg, hemophilia, von Willebrand disease).
  • History of Stevens-Johnson syndrome or toxic epidermal necrolysis.
  • In the opinion of the investigator, any clinically significant condition that may affect tirabrutinib absorption, including gastric restrictions and bariatric surgery (eg, gastric bypass). Participants with cholecystectomy will be allowed to participate.
  • Positive results at Screening for (HIV).
  • History of or anaphylaxis to tirabrutinib.
  • In the opinion of the investigator, participant has been on a diet incompatible with the on-study diet within 28 days before dosing.
  • Donation of blood >500 mL or significant blood loss within 56 days before dosing.
  • Plasma donation within 7 days before dosing.
  • Is working at or has an immediate family member (spouse or children) who works at the study site or is a staff member of the sponsor and directly involved in this trial.
  • Dosed in another clinical trial within 28 days or within a period equivalent to 5 half-lives of the drug (whichever is longer) before dosing.
  • Have corrected according to Fridericia's formula (QTcF) >450 ms or deemed clinically abnormal by the investigator at Screening.
  • Intake of grapefruit, Seville orange, or herbal preparations containing St. John's Wort within 14 days before dosing.
  • Engagement in strenuous exercise (eg, moving large bulky items, bodybuilding) within 14 days before dosing.
  • Receipt of any medication (including prescription or over-the-counter medicines, vitamin supplements, natural or herbal supplements) within 14 days before dosing.
  • Receipt of any inducers, P-glycoprotein inducers, or strong CYP3A4 inhibitors within 14 days before dosing.
  • Have hepatic encephalopathy of Grade 2 or above at Screening.
  • History or presence of drug abuse within 6 months before dosing.
  • or AST ≥ 3 × (ULN) on clinical laboratory tests at Screening. Participants with ALT or AST values ≥2 × ULN and \<3 × ULN may be enrolled at the discretion of the investigator following consultation with the medical monitor. Acknowledging the medical state of the population enrolled, participants with and C are not specifically excluded.
  • History or presence of alcoholism and/or drug abuse within 6 months before dosing. Alcohol abuse is defined as 8 or more drinks per week for a woman or 15 or more drinks per week for a man.
  • Systolic blood pressure (BP) \< 90 mm Hg or > 150 mm Hg and/or diastolic BP \< 40 mm Hg or > 95 mm Hg sustained for > 5 minutes while resting in a seated position at Screening.
  • Seated pulse rate is \< 40 beats per minute (bpm) or > 99 bpm at Screening.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Tirabrutinib (Mild Hepatic Impairment)

    Participants received a single dose of Tirabrutinib 80 mg administered orally on Day 1.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib (Moderate Hepatic Impairment)

    Participants received a single dose of Tirabrutinib 80 mg administered orally on Day 1.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib (Severe Hepatic Impairment)

    Participants received a single dose of Tirabrutinib 80 mg administered orally on Day 1.

    Drug: Tirabrutinib

  • Experimental
    Tirabrutinib (Normal Hepatic Function)

    Participants received a single dose of Tirabrutinib 80 mg administered orally on Day 1.

    Drug: Tirabrutinib

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameter of tirabrutinib: Cmax

    Time frame: 72 hour

  2. Pharmacokinetic parameter of tirabrutinib: Tmax

    Time frame: 72 hour

  3. Pharmacokinetic parameter of tirabrutinib: AUClast

    Time frame: 72 hour

  4. Pharmacokinetic parameter of tirabrutinib: AUCinf

    Time frame: 72 hour

  5. Pharmacokinetic parameter of tirabrutinib: T1/2

    Time frame: 72 hour

  6. Pharmacokinetic parameter of tirabrutinib: CL/F

    Time frame: 72 hour

  7. Pharmacokinetic parameter of tirabrutinib: Volume of distribution (Vd)

    Time frame: 72 hour

  8. Protein binding ratio of tirabrutinib in plasma

    Time frame: 72 hour

Secondary outcomes

  1. Safety and tolerability: Vital signs (pulse rate)

    Time frame: 72 hour

  2. Safety and tolerability: Vital signs (blood pressure)

    Time frame: 72 hour

  3. Safety and tolerability: Vital signs (respiratory rate)

    Time frame: 72 hour

  4. Safety and tolerability: Vital signs (body temperature)

    Time frame: 72 hour

  5. Safety and tolerability: Number of participants with clinically significant abnormal 12-lead electrocardiogram (ECG) parameters (RR, PR, QRS, QT, QTcF)

    The number of participants with clinically significant abnormal values in any of the following ECG parameters will be reported: RR, PR, QRS, QT intervals, and QTcF.

    Time frame: 72 hour

  6. Safety and tolerability: Number of participants with clinically significant abnormal laboratory values

    The number of participants with clinically significant changes in any laboratory value (hematology, clinical chemistry, coagulation, and urinalysis) will be reported.

    Time frame: 72 hour

  7. Safety and tolerability: Adverse events (AEs)

    Time frame: 72 hour

07

Study locations

3 sites
  • Arizona Liver Health
    Chandler, Arizona 85225, United States
  • Panax Clinical Research
    Miami Lakes, Florida 33014, United States
  • Orlando Clinical Research Center, Inc.
    Orlando, Florida 32809, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Apr 2026, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2025
First posted
Sep 30, 2025
StartActual
Oct 1, 2025
Primary completionActual
Apr 9, 2026
CompletionActual
Apr 20, 2026
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07198087
Responsible party
Sponsor
First posted
Sep 30, 2025
Start date
Oct 1, 2025
Primary completion
Apr 9, 2026
Completion
Apr 20, 2026
Last update
Jun 26, 2026

Study contacts

Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirabrutinib

Start the discussion